EP0626451A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Heterodimers of a TGF-beta superfamily
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1994-05-26
•
Granted: —
•
Expires: 2014-05-26
Abstract
Abstract A heterodimer composed of factors belonging to a TGF-β superfamily, and a composition for treatment of osteopathy containing the same, an expression vector which is autonomically replicable in an insect cell and contains one or more DNA(s) coding for a factor(s) belonging to a TGF-β superfamily, and a method for preparing the heterodimer having bone-inducing activity is disclosed.
Inventors
- 👤 Yukio Fujisawa
- 👤 Masatoshi Hazama
- 👤 Aki Aono
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 21:12
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/51; C07K14/495
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
26 words
An expression vector which is autonomically replicable in an insect cell and comprises one or more DNA(s) coding for a factor(s) belonging to a TGF-β superfamily.
Claim 2
Dependent Claim
23 words
An expression vector which is autonomically replicable in an insect cell and comprises DNAs coding for two factors belonging to a TGF-β superfamily.
Claim 3
Dependent Claim
26 words
The expression vector according to claim 1 or 2, wherein the TGF-β superfamily includes a bone morphogenetic protein family, a TGF-β family and an inhibin family.
Claim 4
Dependent Claim
32 words
The expression vector according to claim 3, wherein the bone morphogenetic protein family includes bone morphogenetic factor 2, 3, 4, 5, 6, 7, 8 and 9, Xenopus Vg1, drosophiladecapentapregic and drosophila 60A.
Claim 5
Dependent Claim
18 words
The expression vector according to claim 3, wherein the TGF-β family includes TGF-β₁, β₂, β₃, β₄ and β₅.
Claim 6
Dependent Claim
20 words
The expression vector according to claim 3, wherein the inhibin family includes inhibin α, β A and β B .
Claim 7
Dependent Claim
14 words
The expression vector according to claim 1 or 2, which is a Baculovirus vector.
Claim 8
Dependent Claim
23 words
The expression vector according to claim 1 or 2, wherein the insect cell is a Spodoptera litura -derived cell or a spanworm-derived cell.
Claim 9
Dependent Claim
12 words
An insect cell transformed with the expression vector according to claim 1.
Claim 10
Dependent Claim
12 words
An insect cell transformed with the expression vector according to claim 2.
Claim 11
Dependent Claim
60 words
An insect cell transformed with an expression vector which is autonomically replicable in an insect cell and comprises a DNA coding for a factor belonging to a TGF-β superfamily and an expression vector which is autonomically replicable in an insect cell and comprises a DNA coding for a factor belonging to a TGF-β superfamily other than the above said factor.
Claim 12
Dependent Claim
52 words
A method for preparing a heterodimer composed of two factors belonging to a TGF-β superfamily comprising the steps of cultivating the insect cell of claim 9, 10 or 11 in a medium under conditions sufficient to express the heterodimer, accumulating the heterodimer in a culture product, and collecting the resulting accumulated heterodimer.
Claim 13
Dependent Claim
35 words
A heterodimer composed of two factors belonging to a TGF-β superfamily in which the first factor is drosophiladecapentapregic and the second factor is a factor belonging to a TGF-β superfamily other than the first factor.
Claim 14
Dependent Claim
34 words
The heterodimer according to claim 13, wherein the second factor is selected from the group consisting of bone morphogenetic protein 2, 3, 4, 5, 6, 7, 8 and 9, Xenopus Vg1 and drosophila 60A.
Claim 15
Dependent Claim
18 words
The heterodimer according to claim 14, wherein the second factor is bone morphogenetic protein 4, 6 or 7.
Claim 16
Dependent Claim
15 words
The heterodimer according to claim 15, wherein the second factor is bone morphogenetic protein 7.
Claim 17
Dependent Claim
20 words
A heterodimer composed of two factors belonging to a bone morphogenetic protein family which is derived from Xenopus laevis .
Claim 18
Dependent Claim
31 words
The heterodimer according to claim 17, wherein the bone morphogenetic protein family includes bone morphogenetic protein 2, 3, 4, 5, 6, 7, 8 and 9, Xenopus Vg1, drosophiladecapentapregic and drosophila 60A.
Claim 19
Dependent Claim
20 words
The heterodimer according to claim 18, wherein the bone morphogenetic protein family is bone morphogenetic protein 4, 6 or 7.
Claim 20
Dependent Claim
19 words
The heterodimer according to claim 19, wherein the bone morphogenetic protein family is bone morphogenetic protein 4 and 6.
Claim 21
Dependent Claim
19 words
The heterodimer according to claim 19, wherein the bone morphogenetic protein family is bone morphogenetic protein 4 and 7.
Claim 22
Dependent Claim
50 words
A composition for osteogenesis which comrises a pharmaceutically acceptable carrier containing an effective amount of a heterodimer composed of two factors belonging to a TGF-β superfamily in which the first factor is drosophiladecapentapregic and the second factor is a factor belonging to a TGF-β superfamily other than the first factor.
Claim 23
Dependent Claim
34 words
The composition according to claim 22, wherein the second factor is selected from the group consisting of bone morphogenetic protein 2, 3, 4, 5, 6, 7, 8 and 9, Xenopus Vg1 and drosophila 60A.
Claim 24
Dependent Claim
18 words
The composition according to claim 23, wherein the second factor is bone morphogenetic protein 4, 6 or 7.
Claim 25
Dependent Claim
15 words
The composition according to claim 24, wherein the second factor is bone morphogenetic protein 7.
Claim 26
Dependent Claim
35 words
A composition for osteogenesis which comprises a pharmaceutically acceptable carrier containing an effective amount of a heterodimer composed of two factors belonging to a bone morphogenetic protein family which is derived from Xenopus laevis .
Claim 27
Dependent Claim
31 words
The composition according to claim 26, wherein the bone morphogenetic protein family includes bone morphogenetic protein 2, 3, 4, 5, 6, 7, 8 and 9, Xenopus Vg1, drosophiladecapentapregic and drosophila 60A.
Claim 28
Dependent Claim
20 words
The composition according to claim 27, wherein the bone morphogenetic protein family is bone morphogenetic protein 4, 6 or 7.
Claim 29
Dependent Claim
20 words
The composition according to claim 28, wherein the bone morphogenetic protein family is consisting ofbone morphogenetic protein 4 and 6.
Claim 30
Dependent Claim
20 words
The composition according to claim 28, wherein the bone morphogenetic protein family is consisting ofbone morphogenetic protein 4 and 7.
Claim 31
Dependent Claim
52 words
A composition for therapy of osteopathy which comprises a pharmaceutically acceptable carrier containing an effective amount of a heterodimer composed of two factors belonging to a TGF-β superfamily in which the first factor is drosophiladecapentapregic and the second factor is a factor belonging to a TGF-β superfamily other than the first factor.
Claim 32
Dependent Claim
37 words
A composition for therapy of osteopathy which comprises a pharmaceutically acceptable carrier containing an effective amount of a heterodimer composed of two factors belonging to a bone morphogenetic protein family which is derived from Xenopus laevis .
Claim 33
Dependent Claim
54 words
An assay for determining the effect of a test compound on alkaline phosphatase induction in an osteoblast comprising: (a) contacting an osteoblast with a heterodimer according to claim 13 and measuring alkaline phosphatase induction; (b) contacting the osteoblast of step (a) with the test compound; and (c) measuring the change in alkaline phosphatase induction.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.